賽諾菲將藥物成分業務分支擬於5月6日上市
格隆匯4月1日丨賽諾菲(SNY.US)週五表示,已獲得法國股市監管機構的批准,預計將於5月6日將藥物成分業務分支EUROAPI申請上市。賽諾菲表示,新股將以每股23股的價格分配給其股東。該公司證實計劃在上市後保留30%的股份,而法國政府將通過EPIC Bpifrance以1.5億歐元(1.66億美元)的價格購買12%的股份。賽諾菲最大的股東歐萊雅(oreal)持有賽諾菲超過9%的股權,歐萊雅和EUROAPI首席執行長Karl Rotthier都同意在上市後給予一年的禁售期。EUROAPI生產藥物的活性藥物成分,將在意大利、德國、英國、法國和匈牙利的6個生產基地建立。賽諾菲在1月份表示,預計EUROAPI業務將成為全球第二大API提供商,今年的營收預計約為10億歐元。賽諾菲去年的營收佔EUROAPI業務營收的一半。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.